Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

NCT01182168 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Renal Pelvis Cancer
Ureter Cancer

Interventions

DRUG: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]